Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| UNCY | PRESS-RELEASE | bearish | 6/10 | Unicycive reported Q1 2026 EPS of -$0.54, significantly missing the consensus estimate of -$0.47, driven by a $4.8M non- | May 12, 2026 |
| ARVN | PRESS-RELEASE | bearish | 8/10 | Arvinas reported Q1 2026 revenue of $15.6M (down 91.7% YoY from $188.8M) and a GAAP EPS of -$0.90, significantly missing | May 12, 2026 |
| CCCC | 8-K | neutral | 4/10 | C4 Therapeutics reported Q1 2026 revenue of $6.2M (down 14% YoY from $7.2M) and a net loss per share of -$0.20 (improved | May 12, 2026 |
| OLMA | 8-K | neutral | 4/10 | Olema Pharmaceuticals reported Q1 2026 financial results, with a net loss of $53.1M (vs $30.4M in Q1 2025) driven by inc | May 12, 2026 |
| IRD | 8-K | mixed | 5/10 | Opus Genetics reported Q1 2026 revenue of $2.2M (down 51% YoY from $4.4M) and a GAAP net loss of $65.5M ($-0.75/share), | May 12, 2026 |
| OVID | PRESS-RELEASE | mixed | 6/10 | Ovid Therapeutics reported Q1 2026 financial results featuring a net loss of $17.0M (-$0.12/share) versus $10.2M loss a | May 12, 2026 |
| TENX | PRESS-RELEASE | neutral | 5/10 | Tenax Therapeutics reported Q1 2026 EPS of -$0.35, beating consensus of -$0.40 by 12.5%, but net loss widened to $15.7M | May 12, 2026 |
| ACHV | PRESS-RELEASE | mixed | 6/10 | Achieve Life Sciences reported Q1 2026 EPS of -$0.28, beating consensus of -$0.30 by 6.7%. The company also closed a $35 | May 12, 2026 |
| LEGN | PRESS-RELEASE | bullish | 7/10 | Legend Biotech reported Q1 2026 revenue of $305.1M (vs $306.5M consensus, slight miss) and EPS of -$0.15 (GAAP) vs conse | May 12, 2026 |
| SION | PRESS-RELEASE | neutral | 6/10 | Sionna reported Q1 2026 GAAP EPS of -$0.60, a 3.2% beat vs consensus of -$0.62, but net loss widened to $26.8M from $16. | May 12, 2026 |
| IMTX | PRESS-RELEASE | mixed | 6/10 | Immatics reported Q1 2026 EPS of -$0.29, a 33.9% beat vs consensus of -$0.44, but revenue fell sharply to $8.7M from $21 | May 12, 2026 |
| IRD | PRESS-RELEASE | bearish | 7/10 | Opus Genetics reported Q1 2026 EPS of -$0.75, a 212.5% miss vs consensus of -$0.14, driven by a $51.4M non-cash fair val | May 12, 2026 |
| OLMA | PRESS-RELEASE | neutral | 5/10 | Olema Oncology reported Q1 2026 EPS of -$0.52, a 7.2% beat vs consensus of -$0.54, but net loss widened to $53.1M from $ | May 12, 2026 |
| PRLD | PRESS-RELEASE | bullish | 7/10 | Prelude Therapeutics reported Q1 2026 EPS of -$0.13, beating consensus of -$0.27, with revenue of $4.58M (vs $0 consensu | May 12, 2026 |
| CCCC | PRESS-RELEASE | mixed | 5/10 | C4 Therapeutics reported Q1 2026 results with an EPS beat ($-0.18 vs $-0.26 consensus) and revenue beat ($6.2M vs $4.4M | May 12, 2026 |
| ABOS | PRESS-RELEASE | neutral | 5/10 | Acumen Pharmaceuticals reported Q1 2026 EPS of -$0.33 (GAAP) vs consensus of -$0.46, a 28.3% beat, with net loss narrowi | May 12, 2026 |
| CALC | 8-K | neutral | 4/10 | CalciMedica reported Q1 2026 GAAP net income of $5.0M ($0.31 basic EPS), a swing from a $5.0M net loss in Q1 2025, drive | May 12, 2026 |
| PMN | 8-K | neutral | 4/10 | ProMIS Neurosciences reported Q1 2026 financial results, highlighting a net loss of $8.2 million (vs $7.3 million in Q1 | May 12, 2026 |
| RDY | 6-K | neutral | 1/10 | Dr. Reddy's management will participate in investor conferences hosted by HSBC (Mumbai, May 14-15) and Bank of America ( | May 12, 2026 |
| ANNX | ANALYST-UPGRADE | bearish | 4/10 | Goldman Sachs initiated coverage of ANNX on May 12, 2026, with a Neutral rating and a $7 price target, well below the co | May 12, 2026 |
| MPLT | CLUSTER | neutral | 3/10 | Five MapLight insiders, including the CEO, CFO, CSO, and CMO, sold a total of ~$937K in open-market sales over a 7-day w | May 11, 2026 |
| PLSE | CLUSTER | bullish | 7/10 | Two Pulse Biosciences insiders, including CEO Paul LaViolette and director/10% owner Robert Duggan, made open-market pur | May 11, 2026 |
| ODTX | CLUSTER | bullish | 7/10 | Insider cluster at Odyssey Therapeutics shows $20.2M in open-market purchases by directors Li Nan and Chu Shelley at $18 | May 11, 2026 |
| CLRB | CLUSTER | bearish | 6/10 | CLRB's CEO and COO purchased $50K in shares at $2.88, a premium to the heavily dilutive $34.95M offering priced at $2.65 | May 11, 2026 |
| SION | CLUSTER | bearish | 7/10 | Two Sionna directors (OrbiMed Advisors and Peter Thompson) sold a combined $26.7M of stock over three days, representing | May 11, 2026 |
| PLSE | CLUSTER | bullish | 7/10 | Two PLSE insiders, including CEO Paul LaViolette and Director Robert Duggan, collectively purchased $13.3M in open-marke | May 11, 2026 |
| ATRA | CLUSTER | mixed | 5/10 | Atara Biotherapeutics saw a mixed insider cluster: 10% owner EcoR1 Capital bought $4.74M worth of shares, while director | May 11, 2026 |
| LQDA | 144 | bearish | 6/10 | Venture capital firm Canaan VIII LP, a director of Liquidia Corp, filed a Form 144 to sell 318,893 shares of common stoc | May 11, 2026 |
| ACTU | 8-K | mixed | 7/10 | Actuate Therapeutics announced FDA clearance of an Investigational New Drug (IND) application to conduct a Phase 1/2 stu | May 11, 2026 |
| CRDL | 6-K | neutral | 5/10 | Cardiol Therapeutics reported Q1 2026 results: net loss widened to C$10.8M from C$8.3M a year ago, driven by higher R&D | May 11, 2026 |